Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023 - ResearchAndMarkets.com

DUBLIN--()--The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023" report has been added to ResearchAndMarkets.com's offering.

This analysis of the global PARP inhibitors market provides an in-depth analysis of the current market scenario, trends, dynamics and recent advances that might have an impact on the PARP inhibitors market. Key data like pricing of drugs, sales and cost of therapy per patient have been used to draw an accurate analysis of the PARP inhibitors market. Finally, KuicK Research analysis of forecast and projections regarding the future of PARP Inhibitors market indicate an exciting opportunity waiting in this highly profitable segment of cancer therapy.

PARP inhibitors have proved to be a commercial success in the modern cancer therapeutic segment. For instance, Lynpraza(Olaparib), marketed by AstraZeneca reported global sales of over US$ 400 Million in 2017; making it one of the most profitable cancer therapy drugs of the year. Lynpraza sales have more than doubled since its approval which projects an optimistic growth in the future. Olaparib is followed by Niraparib with sales of over US$ 109 Million during first nine months of commercial launch. Rucaparib - the most recent PARP inhibitor to enter the market is estimated to generate revenue of over US$ 40 Million by the end of 2018.

The US currently dominates the global PARP inhibitors market leading both in marketing and research followed by Europe. Involvement of regions like South Korea, Japan and Middle East has led to better market penetration and overall better market growth.

The demand for PARP inhibitors has grown exponentially with the increasing incidence of cancer. Further, their enhanced efficacy in cancer treatment when combined with conventional therapeutics like chemotherapy and radiation therapy has led to an exponential growth in sales; which is further strengthened by a robust clinical pipeline under development. With several favorable factors paving the path for success, PARP inhibitors could be one of the leading cancer therapeutics of the future

Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023 report highlights:

  • Current Market Trends & Development Scenario
  • Drug Availability, Dosage & Treatment Schedule
  • Commercially Available Drugs Price Analysis
  • Global Cancer PARP Inhibitors Clinical Pipeline Overview: 31 Drugs
  • Clinical & Patent Insight on Commercially Available Drugs: 3 Drugs
  • Market Segmentation by Drug Patent & Deals

Key Topics Covered:

1. Introduction to Poly (ADP-Ribose) Polymerase Inhibitors

2. PARP Proteins: An Attractive Target for Developing Cancer Therapeutics

3. Therapeutic Exploitation of Role of PARP Proteins in Normal Cells & Cancer Cells

4. Global Poly (ADP-Ribose) Polymerase Inhibitors Clinical Pipeline Overview

5. Commercially Available Poly (ADP-Ribose) Polymerase Inhibitors (PARP Inhibitors) as Cancer Monotherapy

6. Global PARP Inhibitor Cancer Therapy Current Market Scenario

7. PARP Inhibitors with Conventional Cancer Therapy: Efficacy, Dosage & Price Analysis

8. Improved Efficacy of PARP Inhibitors by Modern Cancer Therapies

9. Factors Driving Global PARP Inhibitors Market

10. Global PARP Inhibitor Market Challenges

11. Global PARP Inhibitors Market Future Forecast

12. Global Cancer PARP Inhibitors Clinical Pipeline by Company, Indication & Phase

13. Marketed Cancer PARP Inhibitors Clinical Insight by Company & Indication

14. Competitive Landscape

  • 2X Oncology
  • Abott Laboratories
  • Cephalon
  • Checkpoint Therapeutics
  • Eisai Co. Ltd
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals
  • KuDOS Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lead Therapeutics
  • Shanghai De Novo Pharmatech

For more information about this report visit https://www.researchandmarkets.com/research/lzllmd/global_parp?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs